Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.34 |
| ▸ | CA2 | P00918 | 5/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474319 | 0.88 | CA1 (0.36) | CA1CA2CA9CA12MAPT | |
| SCHEMBL12035557 | 0.84 | CA1 (0.40) | CA1CA2CA9CA12MAPT | |
| SCHEMBL2306972 | 0.81 | CA1 (0.39) | CA1CA2CA9CA12MAPT | |
| SCHEMBL1475701 | 0.81 | FFAR1 (0.38) | — | |
| SCHEMBL1473143 | 0.80 | MAPT (0.41) | CA1CA2CA9CA12MAPT | |
| SCHEMBL20388697 | 0.78 | CA1 (0.36) | CA1CA2CA9CA12MAPT | |
| SCHEMBL18272434 | 0.78 | ALDH1A1 (0.47) | CA1CA2CA9CA12MAPT | |
| SCHEMBL18272445 | 0.78 | ALDH1A1 (0.47) | CA1CA2CA9CA12MAPT | |
| SCHEMBL30782701 | 0.78 | ALDH1A1 (0.47) | CA1CA2CA9CA12MAPT | |
| SCHEMBL28404770 | 0.78 | ALDH1A1 (0.47) | CA1CA2CA9CA12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861359-B1 | N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20110152326-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | HANAZAWA TAKESHI | 2011-06-23 | — | — | US | disclosed |
| US-7915448-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7622589-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | CNR1, HVCN1, CNR2 | CA1 947/4885CA2 616/4885CA9 739/4885 |
| US-20110152326-A1 | SUBSTITUTED ARYLOXOETHYL CYCLOPROPANECARBOXAMIDE COMPOUNDS AS VR1 RECEPTOR ANTAGONISTS | OPRL1, CNR1, TRPV1 | CA1 3557/4885CA2 1388/4885CA9 2827/4885 |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | CNR1, HVCN1, CNR2 | CA1 958/4885CA2 627/4885CA9 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.